Previous Blogs

Avatar

By Page McAndrew PhD

September 16, 2021

Development of vaccines for COVID-19 and its variants continues to present challenges such as accelerated timelines. Since there is not the usual time available for selection, evaluation, and qualification of the package and delivery systems, risks must be mitigated at every phase. For vaccines packaged in prefilled syringes, use of an elastomer plunger laminated with FluroTec® film can help.

Avatar

By Eecho Wang

June 15, 2021

We are delighted to share that West China has recently received two acknowledgements from China National Pharmaceutical Packaging Association (CNPPA), an industrial authority in China, for West’s continuous efforts in supporting the healthcare industry during the pandemic and insightful sharing on scientific thought leadership.

Avatar

By Laura Pitt

April 15, 2021

On a cold, early morning in the first week of March, hope arrived at Community Volunteers in Medicine (CVIM) in West Chester, Pennsylvania in the shape of a small, frozen box. After many months of dedicated work, CVIM became an official vaccination site in Chester County, and could now work to vaccinate at-risk individuals in our shared community.

Avatar

By Whitney Winters

September 02, 2020

The need to provide vaccines for the SARS-CoV-2 pandemic has presented the pharmaceutical industry with unprecedented challenges. Among them are accelerated timelines for development/approval and unanticipated volumes for manufacture/delivery. Ordinarily for a new drug product, there is ample time for selecting the primary package system and establishing component availability.

Avatar

By Valerie Bomberger

May 27, 2020

How does West respond to increased demand to produce supplies needed for use with treatments to combat the coronavirus? The answer is – with years of experience, careful planning, and a robust manufacturing program. We are committed to doing our part to speed the successful development and large-scale manufacture of high-quality components required to serve customer needs for the delivery of a safe, effective COVID-19 vaccine, which includes expanding labor and equipment resources.

Avatar

By Page McAndrew PhD.

May 22, 2020

Developing a SARS-CoV-2 vaccine presents numerous and unprecedented challenges; prominent among them are greatly accelerated timelines. Ordinarily for a new drug product, there is sufficient time for selection/evaluation of the vial/stopper packaging system – one that guarantees quality and safety from manufacture through delivery. This is not the case for a SARS-CoV-2 vaccine where the primary packaging system must be chosen quickly, creating a higher risk.